Rajna Golubic, Jane Kennet, Victoria Parker, Darren Robertson, Dan Luo, Lars Hansen, Lutz Jermutus, Phil Ambery, Maria Ryaboshapkina, Manasa Surakala, Rhianna C Laker, Michelle Venables, Albert Koulman, Adrian Park, Mark Evans
AIMS: To establish which components of energy balance mediate the clinically significant weight loss demonstrated with use of cotadutide, a glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, in early-phase studies. MATERIALS AND METHODS: We conducted a phase 2a, single-centre, randomized, placebo-controlled trial in overweight and obese adults with type 2 diabetes. Following a 16-day single-blind placebo run-in, participants were randomized 2:1 to double-blind 42-day subcutaneous treatment with cotadutide (100-300 μg daily) or placebo...
April 1, 2024: Diabetes, Obesity & Metabolism